Tarlatamab: a potential new option for recurrent small cell lung cancer
Transl Lung Cancer Res
.
2023 Jul 31;12(7):1628-1630.
doi: 10.21037/tlcr-23-215.
Epub 2023 Jun 5.
Authors
Alfredo Addeo
1
,
Giuseppe Luigi Banna
2
,
Alex Friedlaender
1
3
Affiliations
1
Department of Oncology, University Hospital Geneva, Geneva, Switzerland.
2
Department of Oncology, Portsmouth Hospitals University NHS Trust, Cosham, Portsmouth, UK.
3
Oncology Unit, Clinique Générale Beaulieu, Geneva, Switzerland.
PMID:
37577302
PMCID:
PMC10413042
DOI:
10.21037/tlcr-23-215
No abstract available
Keywords:
Small cell lung cancer (SCLC); bispecific T-cell engager (BiTE); tarlatamab.
Publication types
Editorial
Comment